Fact Sheet/Brochure

This fact sheet includes a basic description of fentanyl, a brief explanation of the danger, and strategies to helped loved ones who may be using or at risk of using fentanyl.

This letter announces details on the 2023 Medication Access and Training Expansion (MATE) Act which requires new or renewing DEA licensees to have completed a total of at least eight hours of training on opioid or other substance use disorders and the appropriate treatment of pain.

This guidance document provides information regarding issuance of updated DEA registration certificates to reflect Congress’s elimination of the X-waiver (DATA-Waiver) in the Consolidated Appropriations Act of 2023, increasing accessibility of medication-assisted treatment (MAT).

This letter announces details on Congress's elimination of the X-waiver (DATA-Waiver) to increase buprenorphine accessibility in the Consolidated Appropriations Act of 2023, increasing accessibility of medication-assisted treatment (MAT).

This handout provides definitions for the most common terms used in discussing why health equity matters in prevention.

This handout is designed to assist both newly formed and seasoned prevention coalitions to determine the who, what, and how to reduce health disparities as they implement substance misuse prevention programs.

This fact sheet provides guidance for patients starting buprenorphine outside of hospitals or clinics.

This NIDA fact sheet provides information on the relationship between drug use and viral infections.

This fact sheet provides healthcare providers and people who use drugs with an overview of fentanyl and fentanyl test strips to prevent overdose. Other harm reduction strategies are also provided.

This fact sheet provides an overview of the Medication First (or low-barrier maintenance pharmacotherapy) approach to the treatment of opioid use disorders.